Hybrid Vector Development Platform
The emergence of viral and non-viral-based hybrid vector systems offers great potential for the treatment of genetic diseases and acquired diseases. Our company is committed to helping customers develop hybrid vector systems using suitable non-immunogenic nanomaterials to achieve minimal side effects, optimal tissue targeting, and enhanced efficacy. Our specialized scientific services will contribute to the development of novel gene therapies for rare diseases.
Overview of Hybrid Vectors
Hybrid vectors refer to chimeric vectors composed of elements from two or more viruses, or chimeric vectors combined with other proteins or genetic components. Efficient intracellular delivery of therapeutic nucleic acids is essential for the success of gene therapy. To date, hybrid vectors have been widely used as common strategies for delivering genes of interest to multiple target tissues, and they have been successfully used to treat a variety of genetic diseases.
Fig.1 Hybrid viral nanoparticles. (Mahato, M., et al., 2018)
Advantages of Hybrid Vectors
Viral vectors are highly efficient at transducing genes but are immunogenic. Non-viral vectors have lower transfection efficiency, but they are generally less immunogenic. Both types of vectors have advantages and disadvantages that hinder their therapeutic endpoints in clinical trials.
To take advantage of the strengths of both types of vectors, researchers have attempted to develop hybrid vector combinations of viral and chemical vectors to achieve higher gene delivery efficiency than individual vectors alone. These hybrid vectors overcome the limitations associated with both delivery systems while enhancing desired features such as low immunogenicity, targeting ability, higher payload, and the ability to deliver multiple transgenes, thus making gene therapy a clinically available technology.
Our company improves gene delivery efficiency in rare disease therapy research by constructing vectors by encapsulating viral vectors, such as AAV, adenovirus, retrovirus or lentivirus, in synthetic materials such as liposomes, dendrimers and hydrogels. The viral- and non-viral-based hybrid vector development services we can provide include but are not limited to:
Dendrimer-coated virus particles
Adenoviral hybrid vectors were constructed using poly(amidoamine) dendrimer generation 5 (PAMAM-G5) and improved targeting capabilities by coupling them to specific peptides.
Virus particles encapsulated liposomes
Help customers prepare anionic liposomal-based encapsulated viral particles by encapsulating adenoviral vectors in anionic bilamellar liposomes composed of phosphatidylcholine, phosphatidyletha-nolamine, cholesterol, inositol phospholipids, PEG-2000, and non-toxic lecithin.
Virus vector-laden hydrogels
Provide virus vector-laden hydrogels development services such as lentiviruses encapsulated in hydrogels consisting of collagen and hydroxyapatite to explore better lentiviral transduction profiles.
In addition to viral- and non-viral-based hybrid vector development services, we can also provide other forms of hybrid vector development services:
The services we provide include but are not limited to:
- Adenoviral/retroviral hybrid vectors
- Adenoviral/adeno-associated viral hybrid vectors
- Additional integrating adenoviral hybrid vectors
- Non-integrating adenoviral hybrid vectors
- DBD-based hybrid vectors
- Homologous recombination-based retroviral hybrid vectors
- Hybrid adeno-associated viral vectors
- Herpes viral/adeno-associated viral hybrid vectors
- Herpes viral/retroviral hybrid vectors
- Herpes viral/Sleeping Beauty transposition hybrid vectors
- Non-integrating herpes viral hybrid vectors
- Herpes viral tribrid vectors
With extensive experience and expertise in the field of gene delivery vectors, our company is well-positioned to provide technical support and integrated solutions for the development of hybrid vector-based delivery systems consisting of nanoparticles and viral vectors. Such hybrid vectors offer a new and promising avenue for gene therapy of rare diseases. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
- Mahato, M., et al. "Viral-and non-viral-based hybrid vectors for gene therapy." Gene and Cell Therapy: Biology and Applications (2018): 111-130.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.